Skip to main content
ELVN
NASDAQ Life Sciences

FDA Signs Off on Phase 3 Trial Design for Enliven's Relcobatinib in CML

Tom Rudovsky · Reported by Seeking Alpha
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$42.39
Mkt Cap
$3.106B
52W Low
$14.785
52W High
$62.32
52W Position info
187% above low
Off High info
32% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

ELVN has more than doubled off its 52-week low of $14.785 on elevated volume (2.1× avg).

Summary

Enliven Therapeutics and the FDA have reached agreement on the phase 3 trial design for relcobatinib in chronic myeloid leukemia. This is a key regulatory milestone that de-risks the pivotal program and sets the path toward a potential registration study. The company's lead candidate now has a clear late-stage development plan, which could accelerate timelines and attract partnership interest. No specific trial start date or patient enrollment figures were disclosed in the headline. The news follows a period of routine insider selling under pre-arranged 10b5-1 plans, which does not alter the fundamental outlook.

At the time of this announcement, ELVN was trading at $42.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $14.79 to $62.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.


Price Chart

Share this article

Copied!

ELVN - Latest Insights

ELVN
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $44.79
Real-time Price: $44.79 info
Change: $0 (0%) info
Market Cap: $3.282B info
ELVN
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $44.79
Real-time Price: $44.79 info
Change: $0 (0%) info
Market Cap: $3.282B info
ELVN
Jun 24, 2026, 7:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $47.60
Real-time Price: $44.79 info
Change: -$2.81 (-6%) info
Market Cap: $3.282B info
ELVN
Jun 22, 2026, 8:10 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $45.37
Real-time Price: $44.79 info
Change: -$0.580 (-1%) info
Market Cap: $3.282B info
ELVN
Jun 15, 2026, 9:21 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $42.60
Real-time Price: $44.79 info
Change: +$2.19 (+5%) info
Market Cap: $3.282B info